AIOS vs Isomorphic Labs

What users praise

• • Claims deep EHR integration via FHIR standards, a key healthcare requirement.
• • Offers multi-model support, allowing organizations to bring their own AI.
• • Includes audit trails and role-based access for compliance.
• • Aims to reduce workflow fragmentation by being an infrastructure platform.

What frustrates them

• • No real user feedback exists to validate any claim or feature.
• • Unclear whether the product actually works in production environments.
• • Name ambiguity with other AIOS products causes confusion.
• • No independent evidence of HIPAA compliance or security audits.

What users praise

• • Built on the Nobel-winning AlphaFold, giving it instant credibility in structural biology.
• • Drug Design Engine extends beyond structure to generative molecule design, promising novel chemistry.
• • Deep partnerships with Novartis and J&J, with potential billions in royalties.
• • Interdisciplinary team of top ML and drug discovery experts, ensuring depth of expertise.

What frustrates them

• • Not accessible to individual researchers or small biotech due to partnership model only.
• • Proprietary nature of parts of its tech limits community scrutiny and independent validation.
• • CASP16 results suggest AlphaFold 3-based models aren't always better than older methods for protein-ligand interactions.
• • No marketed drugs yet; outcomes remain uncertain with royalties tied to long timelines.